Aliases & Classifications for Oligohydramnios

MalaCards integrated aliases for Oligohydramnios:

Name: Oligohydramnios 12 30 56 6 45 15 17 74
Oligohydramnios - Delivered 12 74
Oligohydramnios, Antepartum Condition or Complication 74
Antepartum Oligohydramnios 12
Delivered Oligohydramnios 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12215
ICD9CM 36 658.0
MeSH 45 D016104
NCIt 51 C92839
SNOMED-CT 69 59566000
ICD10 34 O41.0 O41.00

Summaries for Oligohydramnios

Disease Ontology : 12 A placenta disease that is characterized by a deficiency of amniotic fluid sometimes resulting in an embryonic defect through adherence between embryo and amnion.

MalaCards based summary : Oligohydramnios, also known as oligohydramnios - delivered, is related to potter's syndrome and renal tubular dysgenesis, and has symptoms including morning sickness An important gene associated with Oligohydramnios is PKHD1 (PKHD1 Ciliary IPT Domain Containing Fibrocystin/Polyductin), and among its related pathways/superpathways are Peptide ligand-binding receptors and Peptide hormone metabolism. The drugs Warfarin and Tocopherol have been mentioned in the context of this disorder. Affiliated tissues include kidney, placenta and heart, and related phenotypes are behavior/neurological and growth/size/body region

Wikipedia : 77 Oligohydramnios is a condition in pregnancy characterized by a deficiency of amniotic fluid. It is the... more...

Related Diseases for Oligohydramnios

Diseases related to Oligohydramnios via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 156)
# Related Disease Score Top Affiliating Genes
1 potter's syndrome 33.8 AGT REN
2 renal tubular dysgenesis 32.8 ACE AGT AGTR1 REN
3 multiple pterygium syndrome, lethal type 32.0 CHRNA1 CHRND CHRNG
4 polyhydramnios 30.9 AFP AQP1 AQP3
5 renal dysplasia 30.5 ACE AGT AGTR1 REN
6 anuria 30.4 ACE AGT AGTR1 REN
7 chromosomal triplication 30.1 AFP CGA
8 cystic lymphangioma 30.1 AFP CHRND CHRNG
9 eclampsia 30.0 EDN1 OXT REN
10 diabetes mellitus 29.0 ACE AGT AGTR1 EDN1 REN
11 pre-eclampsia 28.9 ADM AFP AGT AGTR1 EDN1 OXT
12 kidney disease 28.9 ACE ADM AGT AGTR1 EDN1 PKHD1
13 renal hypodysplasia/aplasia 1 11.4
14 twin-to-twin transfusion syndrome 11.3
15 trisomy 2 mosaicism 11.3
16 bilateral renal agenesis dominant type 11.2
17 polycystic kidney disease 4 with or without polycystic liver disease 11.2
18 situs inversus totalis with cystic dysplasia of kidneys and pancreas 11.1
19 urethral obstruction sequence 11.1
20 congenital anomalies of kidney and urinary tract 2 11.0
21 meckel syndrome, type 1 11.0
22 renal dysplasia-limb defects syndrome 11.0
23 meckel syndrome, type 7 11.0
24 fetal indomethacin syndrome 11.0
25 hypoaldosteronism 10.5 ACE REN
26 pediatric hypertension 10.5 ACE AGT
27 renal artery obstruction 10.4 ACE REN
28 hypertension, diastolic 10.4 ACE REN
29 posterior urethral valves 10.4 ACE AGT AGTR1
30 hypertensive encephalopathy 10.4 ACE REN
31 microvascular complications of diabetes 3 10.4 ACE AGT AGTR1
32 diastolic heart failure 10.4 ACE AGT AGTR1
33 familial hypertension 10.4 AGT AGTR1 REN
34 hypertensive retinopathy 10.4 ACE REN
35 interstitial nephritis 10.4 ACE AGT REN
36 hypertensive heart disease 10.4 ACE AGT AGTR1
37 vesicoureteral reflux 1 10.4 AGT AGTR1 REN
38 obstructive nephropathy 10.4 ACE AGT REN
39 slow-channel congenital myasthenic syndrome 10.4 CHRNA1 CHRND
40 preterm premature rupture of the membranes 10.4
41 mitral valve disease 10.3 ACE AGT AGTR1
42 cystic kidney disease 10.3 CC2D2A PKHD1 TMEM67
43 aortic valve disease 2 10.3 ACE AGT REN
44 iga glomerulonephritis 10.3 ACE AGTR1 REN
45 multiple pterygium syndrome, escobar variant 10.3 CHRNA1 CHRND CHRNG
46 orthostatic proteinuria 10.3 ACE REN
47 end stage renal failure 10.3 ACE AGT AGTR1
48 neonatal myasthenia gravis 10.3 AFP CHRNG
49 malignant hypertensive renal disease 10.3 EDN1 REN
50 malignant renovascular hypertension 10.3 EDN1 REN

Graphical network of the top 20 diseases related to Oligohydramnios:



Diseases related to Oligohydramnios

Symptoms & Phenotypes for Oligohydramnios

UMLS symptoms related to Oligohydramnios:


morning sickness

MGI Mouse Phenotypes related to Oligohydramnios:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.25 ACE ADM AFP AGT AGTR1 AQP1
2 growth/size/body region MP:0005378 10.24 ACE AGT AGTR1 AQP1 AQP3 CC2D2A
3 cardiovascular system MP:0005385 10.22 ACE ADM AGT AGTR1 AQP1 AQP3
4 mortality/aging MP:0010768 10.16 ACE ADM AFP AGT AGTR1 AQP1
5 homeostasis/metabolism MP:0005376 10.1 ACE ADM AFP AGT AGTR1 AQP1
6 nervous system MP:0003631 9.97 AGT AGTR1 AQP1 CC2D2A CGA CHRNA1
7 renal/urinary system MP:0005367 9.73 ACE ADM AGT AGTR1 AQP1 AQP3
8 reproductive system MP:0005389 9.36 ACE ADM AFP AGT AQP1 CGA

Drugs & Therapeutics for Oligohydramnios

Drugs for Oligohydramnios (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 86)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Warfarin Approved Phase 4 81-81-2 54678486 6691
2
Tocopherol Approved, Investigational Phase 4 1406-66-2 14986
3
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
4
Coumarin Experimental Phase 4 91-64-5 323
5 Tocotrienol Investigational Phase 4 6829-55-6
6 Anticoagulants Phase 4,Not Applicable
7 Vitamins Phase 4,Not Applicable
8 Coagulants Phase 4
9 Antioxidants Phase 4,Phase 2,Phase 3
10 Tocopherols Phase 4
11 Omega 3 Fatty Acid Phase 4
12 Protective Agents Phase 4,Phase 2,Phase 3
13 Tocotrienols Phase 4
14
Dinoprostone Approved Phase 3 363-24-6 5280360
15
Oxytocin Approved, Vet_approved Phase 3 50-56-6 53477758 439302
16
Nitric Oxide Approved Phase 2, Phase 3 10102-43-9 145068
17
AT-101 Approved, Investigational Phase 2, Phase 3 90141-22-3, 652-67-5 12597
18
Isosorbide Dinitrate Approved, Investigational Phase 2, Phase 3 87-33-2 6883
19 Oxytocics Phase 3,Not Applicable
20 Vasodilator Agents Phase 2, Phase 3,Not Applicable
21 Anti-Asthmatic Agents Phase 2, Phase 3
22 Free Radical Scavengers Phase 2, Phase 3
23 diuretics Phase 2, Phase 3
24 Natriuretic Agents Phase 2, Phase 3
25 Autonomic Agents Phase 2, Phase 3
26 Neurotransmitter Agents Phase 2, Phase 3
27 Peripheral Nervous System Agents Phase 2, Phase 3
28 Bronchodilator Agents Phase 2, Phase 3
29 isosorbide-5-mononitrate Phase 2, Phase 3
30 Respiratory System Agents Phase 2, Phase 3
31 Nitric Oxide Donors Phase 2, Phase 3
32 Endothelium-Dependent Relaxing Factors Phase 2, Phase 3
33 Vaccines Phase 2,Not Applicable
34
Sodium Citrate Approved, Investigational Not Applicable 68-04-2
35
Misoprostol Approved Not Applicable 59122-46-2 5282381
36
Caffeine Approved Not Applicable 58-08-2 2519
37
Pertuzumab Approved 380610-27-5, 145040-37-5 2540
38
Trastuzumab Approved, Investigational 180288-69-1 9903
39
Adenosine Approved, Investigational 58-61-7 60961
40
Indomethacin Approved, Investigational 53-86-1 3715
41
Polyestradiol phosphate Approved 28014-46-2
42
Estradiol Approved, Investigational, Vet_approved 50-28-2 5757
43
Calcium Approved, Nutraceutical Not Applicable 7440-70-2 271
44
Citric Acid Approved, Nutraceutical, Vet_approved Not Applicable 77-92-9 311
45
Vitamin D Approved, Nutraceutical, Vet_approved Not Applicable 1406-16-2
46
Vitamin D3 Approved, Nutraceutical Not Applicable 67-97-0 5280795 6221
47
Ergocalciferol Approved, Nutraceutical Not Applicable 50-14-6 5280793
48 Phosphodiesterase Inhibitors Not Applicable
49 Phosphodiesterase 5 Inhibitors Not Applicable
50 Sildenafil Citrate Not Applicable 171599-83-0

Interventional clinical trials:

(show all 43)
# Name Status NCT ID Phase Drugs
1 Warfarine in Unexplained Oligohydramnios Completed NCT01569035 Phase 4 warfarin
2 Role of Antioxidants in Unexplained Oligohydramnios,A Randomized Trial Completed NCT01990690 Phase 4 anti oxidant omega 3
3 Amnioinfusion Initiative Unknown status NCT00787163 Phase 3
4 Induction of Labor in Oligohydramnios Unknown status NCT00815542 Phase 3 prostaglandins E2
5 Stepwise Labor Induction Following Failure of Prostaglandin Vaginal Insert for Labor Induction Unknown status NCT02684305 Phase 3 Administration of Propess;Intravenous oxytocin infusion
6 Trial of AMNIOECHANGE in Gastroschisis Affected Foetuses Unknown status NCT00127946 Phase 3
7 Nitric Oxide Donors for Treatment of Isolated Oligohydramnios Completed NCT02712125 Phase 2, Phase 3 isosorbide mononitrate;Placebo
8 Mechanical cervicAl ripeninG for Women With PrOlongedPregnancies Recruiting NCT02907060 Phase 3 Pharmacological cervical ripening
9 The Safety, Tolerability And Metabolism Of GSK221149A, In Pregnant Women (30-36 Weeks), In Pre-Term Labor Completed NCT00404768 Phase 2 GSK221149A;Placebo
10 A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers Withdrawn NCT03191383 Phase 2 Placebo (Formulation buffer S9b)
11 Alterations of the Uteroplacental and Fetal Pulmonary Circulation Following Amnioinfusion Unknown status NCT01258725 Phase 1
12 Fetal Renal Artery Doppler Indices in Borderline Isolated Oligohydramnios Unknown status NCT02901340
13 Sildenafil Citrate Therapy for Oligohydramnios Unknown status NCT02372487 Not Applicable sildenafil citrate
14 A Screening Strategy for Q Fever Among Pregnant Women Unknown status NCT01095328 Not Applicable
15 Vitamin D Treatment and Hypocalcemic Pregnant Women Unknown status NCT02021864 Not Applicable vitamin D3 50,000 unit;prenatal multivitamin
16 Diabetes Mellitus With Pregnancy in Benisuef Localities Unknown status NCT03169205
17 İs There a Relationship Between Severity of Preeclampsia and Maternal Heavy Metal Levels? Unknown status NCT01906567
18 Active Induction of Labor in Pregnancies Complicated With Oligohydramnios at Term Completed NCT02581774
19 Studying Fetal Breathing Patterns Completed NCT00066976
20 Foley Catheter Versus Vaginal Misoprostol for Cervical Ripening and Induction of Labor Completed NCT01140971 Not Applicable Misoprostol
21 Coffee Consumption and Pregnancy Completed NCT03798275 Not Applicable
22 Perinatal Outcome After Premature Rupture of Membranes Completed NCT01538030
23 Functional Capacity After Computer Assisted Periacetabular Osteotomy in Patients With Hip Dysplasia Completed NCT02015247 Not Applicable
24 Determination of Abnormal Fetal Growth or Amniotic Fluid With Third Trimester Ultrasounds in Uncomplicated Pregnancies: A Randomized Trial Completed NCT02702999 Not Applicable
25 Third Trimester Modified Biophysical Profile Scan for Predicting Fetal Outcome. Completed NCT03729089 Not Applicable
26 A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine Completed NCT00833963 Trastuzumab;Pertuzumab;Ado-Trastuzumab Emtansine
27 Fetoscopic Endoluminal Tracheal Occlusion (FETO) for Congenital Diaphragm Hernia Completed NCT02596802 Not Applicable
28 Uterine, Fetal Cerebral Doppler and Oligohydramnios to Predict Abnormal Heart Rate Tracings in Postterm Pregnancies Recruiting NCT03703037
29 PPROM Registry (Preterm Premature Rupture of Membranes) Recruiting NCT02997345
30 Renal Anhydramnios Fetal Therapy Recruiting NCT03101891 Not Applicable Isotonic fluid
31 Fetoscopic Endoluminal Tracheal Occlusion (FETO) Recruiting NCT03674372 Not Applicable
32 Placenta Imaging Project Recruiting NCT02749851
33 Fetal Endotracheal Occlusion (FETO) in Severe and Extremely Severe Congenital Diaphragmatic Hernia Recruiting NCT00881660 Not Applicable
34 Fitbit Activity Tracker to Predict Risk of Preterm Birth Recruiting NCT03304782
35 Fetal Endoscopic Surgery for Spina Bifida Recruiting NCT03315637 Not Applicable
36 Indomethacin PK and PD Therapy in Pregnancy Active, not recruiting NCT02451228
37 Systemic Lupus and Adverse Pregnancy Outcome Enrolling by invitation NCT03171103
38 Low Sodium Diet in Oligohydramnios Assigned for Conservative Management Not yet recruiting NCT03815968 Not Applicable
39 The Added Contribution of Transvaginal Sonographic Evaluation of Amniotic Fluid Index Not yet recruiting NCT03935607
40 Does Amniotic Fluid Index Affect the Fetal Cardiac Performance? Not yet recruiting NCT03277417
41 A Study of Outcomes and Events of Interest in Pregnant Women, Neonates and Infants and of RSV Surveillance Not yet recruiting NCT03614676 Not Applicable
42 Maternal- Fetal Infection Not yet recruiting NCT03371056 Not Applicable
43 Hydrotherapy for the Reversal of Oligohydramnios Terminated NCT01682928 Not Applicable IV/Oral Hydration and Bedrest

Search NIH Clinical Center for Oligohydramnios

Cochrane evidence based reviews: oligohydramnios

Genetic Tests for Oligohydramnios

Genetic tests related to Oligohydramnios:

# Genetic test Affiliating Genes
1 Oligohydramnios 30

Anatomical Context for Oligohydramnios

MalaCards organs/tissues related to Oligohydramnios:

42
Kidney, Placenta, Heart, Liver, Bone, Pancreas, Fetal Lung

Publications for Oligohydramnios

Articles related to Oligohydramnios:

(show top 50) (show all 488)
# Title Authors Year
1
Oligohydramnios is an independent risk factor for perinatal morbidity among women with pre-eclampsia who delivered preterm. ( 29237307 )
2019
2
Midtrimester isolated oligohydramnios in monochorionic diamniotic multiple gestations. ( 28965437 )
2019
3
Survival Rate without Brain Abnormalities on Postnatal Ultrasonography among Monochorionic Twins after Fetoscopic Laser Photocoagulation for Selective Intrauterine Growth Restriction with Concomitant Oligohydramnios. ( 29462812 )
2019
4
Amnioinfusion for variable decelerations caused by umbilical cord compression without oligohydramnios but with the sandwich sign as an early marker of deterioration. ( 30246578 )
2019
5
Maternal and perinatal outcomes of induction of labor in oligohydramnios at term-a retrospective cohort study. ( 30394156 )
2019
6
Induction of labor methods in isolated term oligohydramnios. ( 30730010 )
2019
7
Oligohydramnios: Should it be considered a risk factor for developmental dysplasia of the hip? ( 30839361 )
2019
8
Effect of oligohydramnios on the accuracy of sonographic foetal weight estimation in at term pregnancies. ( 30910153 )
2019
9
Diabetes Insipidus Presenting with Oligohydramnios and Polyuria During Pregnancy. ( 30135348 )
2018
10
A case of gestational central diabetes insipidus with oligohydramnios. ( 28764595 )
2018
11
Perinatal outcomes in uncomplicated late preterm pregnancies with borderline oligohydramnios. ( 28782398 )
2018
12
Inhaled Nitric Oxide in Preterm Neonates with Refractory Hypoxemia Associated to Oligohydramnios. ( 29046161 )
2018
13
Prenatal parental decision-making and postnatal outcome in renal oligohydramnios. ( 29075889 )
2018
14
Causes of renal oligohydramnios: impact on prenatal counseling and postnatal outcome. ( 29128922 )
2018
15
Induction of labor in cases of late preterm isolated oligohydramnios: is it justified? ( 29343146 )
2018
16
Is pregnancy associated plasma protein-A (PAPP-A) a marker for adverse perinatal outcomes in preterm isolated oligohydramnios cases? ( 29458908 )
2018
17
Outcomes in oligohydramnios: the role of etiology in predicting pulmonary morbidity/mortality. ( 29924737 )
2018
18
Effect of Oligohydramnios on Fetal Heart Rate Patterns during Term Labor Induction. ( 30372774 )
2018
19
Delivery mode and perinatal outcomes after diagnosis of oligohydramnios at term in China. ( 30486718 )
2018
20
How Well Do the Popular Ultrasonic Techniques Estimate Amniotic Fluid Volume and Diagnose Oligohydramnios, in Fact? ( 30601443 )
2018
21
Are Major Depression and Generalized Anxiety Disorder Associated With Oligohydramnios in Pregnant Women? A Case-Control Study. ( 27357862 )
2017
22
Oligohydramnios in complicated and uncomplicated pregnancy: a systematic review and meta-analysis. ( 27062200 )
2017
23
Use of an Amnioport to Maintain Amniotic Fluid Volume in Fetuses with Oligohydramnios Secondary to Lower Urinary Tract Obstruction or Fetal Renal Anomalies. ( 27287190 )
2017
24
Pulmonary Hypoplasia Induced by Oligohydramnios: Findings from Animal Models and a Population-Based Study. ( 27324123 )
2017
25
Induction of Labor in Women with Oligohydramnios: Misoprostol Compared with Prostaglandin E2. ( 27398704 )
2017
26
Prostaglandin E2 induction of labor and cervical ripening for term isolated oligohydramnios in pregnant women with Bishop score ≤ 5. ( 27745800 )
2017
27
Oligohydramnios compromises lung cells size and interferes with epithelial-endothelial development. ( 28152278 )
2017
28
Sildenafil Citrate Therapy for Oligohydramnios: A Randomized Controlled Trial. ( 28277352 )
2017
29
MRI findings of chronic abruption-oligohydramnios sequence (CAOS): report of three cases. ( 28396921 )
2017
30
Report of a Triploid Fetus Identified in a Pregnancy with Oligohydramnios. ( 28459702 )
2017
31
Sildenafil Citrate Therapy for Oligohydramnios: A Randomized Controlled Trial. ( 28644321 )
2017
32
Pregnancy Outcomes in Isolated Oligohydramnios during Second Trimester: A Case Series. ( 28969220 )
2017
33
Sildenafil Citrate Therapy for Oligohydramnios: A Randomized Controlled Trial. ( 29064958 )
2017
34
Evaluation of Maternal and Perinatal Outcomes of Induction in Borderline Oligohydramnios at Term. ( 29207783 )
2017
35
Oligohydramnios and growth restriction do not portend worse prognosis in gastroschisis pregnancies. ( 26932657 )
2016
36
What does fetal autopsy unmask in oligohydramnios? ( 26381033 )
2016
37
Perinatal outcomes with isolated oligohydramnios at term pregnancy. ( 26506098 )
2016
38
Aquaporin 3 Expression Induced by Salvia Miltiorrhiza via ERK1/2 Signal Pathway in the Primary Human Amnion Epithelium Cells from Isolated Oligohydramnios. ( 26917259 )
2016
39
Lack of pharmacist-physician communication associated with nimesulide-induced oligohydramnios during pregnancy. ( 26951121 )
2016
40
Isolated Oligohydramnios at Term as an Indication for Labor Induction: A Systematic Review and Meta-Analysis. ( 27160748 )
2016
41
Obstetric outcomes of isolated oligohydramnios during early-term, full-term and late-term periods and determination of optimal timing of delivery. ( 27225520 )
2016
42
Survival of fetuses with severe oligohydramnios. ( 27328487 )
2016
43
Significance of oligohydramnios in preterm small-for-gestational-age infants for outcome at 18 months of age. ( 27352940 )
2016
44
A randomized controlled study of the efficacy of 4 weeks of supplementation with ω-3 polyunsaturated fatty acids in cases of unexplained oligohydramnios. ( 27559716 )
2016
45
Sildenafil citrate for the management of fetal growth restriction and oligohydramnios. ( 27563258 )
2016
46
Role of l-Arginine in Oligohydramnios. ( 27651617 )
2016
47
Intra-vaginal prostaglandin E2 versus double-balloon catheter for labor induction in term oligohydramnios. ( 25275693 )
2015
48
Perinatal outcomes in pregnancies with oligohydramnios after preterm premature rupture of membranes. ( 25283853 )
2015
49
Predictive value of second and third trimester fetal renal artery Doppler indices in idiopathic oligohydramnios and polyhydramnios in low-risk pregnancies: a longitudinal study. ( 25363086 )
2015
50
Placental lesions associated with oligohydramnios in fetal growth restricted (FGR) pregnancies. ( 25735841 )
2015

Variations for Oligohydramnios

ClinVar genetic disease variations for Oligohydramnios:

6 (show all 19)
# Gene Variation Type Significance SNP ID Assembly Location
1 TMEM67 NM_153704.5(TMEM67): c.1843T> C (p.Cys615Arg) single nucleotide variant Pathogenic/Likely pathogenic rs201893408 GRCh37 Chromosome 8, 94808198: 94808198
2 TMEM67 NM_153704.5(TMEM67): c.1843T> C (p.Cys615Arg) single nucleotide variant Pathogenic/Likely pathogenic rs201893408 GRCh38 Chromosome 8, 93795970: 93795970
3 PKHD1 NM_138694.3(PKHD1): c.107C> T (p.Thr36Met) single nucleotide variant Pathogenic rs137852944 GRCh37 Chromosome 6, 51947999: 51947999
4 PKHD1 NM_138694.3(PKHD1): c.107C> T (p.Thr36Met) single nucleotide variant Pathogenic rs137852944 GRCh38 Chromosome 6, 52083201: 52083201
5 CC2D2A NM_001080522.2(CC2D2A): c.4179+1delG (p.Gly1394Valfs) deletion Pathogenic rs386833760 GRCh37 Chromosome 4, 15589553: 15589553
6 CC2D2A NM_001080522.2(CC2D2A): c.4179+1delG (p.Gly1394Valfs) deletion Pathogenic rs386833760 GRCh38 Chromosome 4, 15587930: 15587930
7 TMEM67 NM_153704.5(TMEM67): c.1321C> T (p.Arg441Cys) single nucleotide variant Pathogenic/Likely pathogenic rs752362727 GRCh38 Chromosome 8, 93786255: 93786255
8 TMEM67 NM_153704.5(TMEM67): c.1321C> T (p.Arg441Cys) single nucleotide variant Pathogenic/Likely pathogenic rs752362727 GRCh37 Chromosome 8, 94798483: 94798483
9 46;XY;t(3;18)(q13.31;q22.1)dn Translocation Pathogenic
10 PKHD1 NM_138694.3(PKHD1): c.2716-3C> G single nucleotide variant Uncertain significance rs1057518964 GRCh37 Chromosome 6, 51908531: 51908531
11 PKHD1 NM_138694.3(PKHD1): c.2716-3C> G single nucleotide variant Uncertain significance rs1057518964 GRCh38 Chromosome 6, 52043733: 52043733
12 OPHN1 NM_002547.2(OPHN1): c.746T> C (p.Leu249Pro) single nucleotide variant Likely pathogenic rs1057518963 GRCh37 Chromosome X, 67430081: 67430081
13 OPHN1 NM_002547.2(OPHN1): c.746T> C (p.Leu249Pro) single nucleotide variant Likely pathogenic rs1057518963 GRCh38 Chromosome X, 68210239: 68210239
14 CC2D2A NM_001080522.2(CC2D2A): c.1149+1G> A single nucleotide variant Pathogenic rs1553827236 GRCh37 Chromosome 4, 15518380: 15518380
15 CC2D2A NM_001080522.2(CC2D2A): c.1149+1G> A single nucleotide variant Pathogenic rs1553827236 GRCh38 Chromosome 4, 15516757: 15516757
16 INF2 NM_022489.3(INF2): c.3247A> G (p.Ser1083Gly) single nucleotide variant Uncertain significance rs1555375554 GRCh38 Chromosome 14, 104714409: 104714409
17 INF2 NM_022489.3(INF2): c.3247A> G (p.Ser1083Gly) single nucleotide variant Uncertain significance rs1555375554 GRCh37 Chromosome 14, 105180746: 105180746
18 LSM1 NM_014462.3(LSM1): c.231+4A> C single nucleotide variant Uncertain significance rs775468919 GRCh37 Chromosome 8, 38027316: 38027316
19 LSM1 NM_014462.3(LSM1): c.231+4A> C single nucleotide variant Uncertain significance rs775468919 GRCh38 Chromosome 8, 38169798: 38169798

Expression for Oligohydramnios

Search GEO for disease gene expression data for Oligohydramnios.

Pathways for Oligohydramnios

GO Terms for Oligohydramnios

Cellular components related to Oligohydramnios according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.8 ACE ADM AFP AGT AQP1 AQP3
2 extracellular space GO:0005615 9.76 ACE ADM AFP AGT CGA EDN1
3 MKS complex GO:0036038 9.26 CC2D2A TMEM67
4 acetylcholine-gated channel complex GO:0005892 8.8 CHRNA1 CHRND CHRNG

Biological processes related to Oligohydramnios according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 ion transmembrane transport GO:0034220 9.97 AQP1 CHRNA1 CHRND CHRNG
2 heart development GO:0007507 9.95 ADM CC2D2A EDN1 OXT
3 regulation of membrane potential GO:0042391 9.87 CHRNA1 CHRND CHRNG
4 female pregnancy GO:0007565 9.85 ADM AGT OXT
5 excitatory postsynaptic potential GO:0060079 9.81 CHRNA1 CHRND CHRNG
6 nervous system process GO:0050877 9.77 CHRNA1 CHRND CHRNG
7 positive regulation of cytosolic calcium ion concentration GO:0007204 9.77 ADM AGT AGTR1 EDN1 OXT
8 regulation of postsynaptic membrane potential GO:0060078 9.76 CHRNA1 CHRND CHRNG
9 regulation of blood pressure GO:0008217 9.71 ACE AGT EDN1 REN
10 water transport GO:0006833 9.69 AQP1 AQP3
11 regulation of blood vessel size GO:0050880 9.69 AGT EDN1
12 neuromuscular synaptic transmission GO:0007274 9.69 CHRNA1 CHRND CHRNG
13 positive regulation of cellular protein metabolic process GO:0032270 9.68 AGT AGTR1
14 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.68 AGT AGTR1
15 vasoconstriction GO:0042310 9.68 AGT EDN1
16 amyloid-beta metabolic process GO:0050435 9.67 ACE REN
17 low-density lipoprotein particle remodeling GO:0034374 9.66 AGT AGTR1
18 regulation of blood vessel diameter GO:0097746 9.66 ACE AGTR1
19 angiotensin maturation GO:0002003 9.65 ACE REN
20 synaptic transmission, cholinergic GO:0007271 9.65 CHRNA1 CHRND CHRNG
21 kidney development GO:0001822 9.65 ACE AGT AGTR1 PKHD1 REN
22 artery smooth muscle contraction GO:0014824 9.64 AGT EDN1
23 positive regulation of cholesterol esterification GO:0010873 9.64 AGT AGTR1
24 positive regulation of blood pressure GO:0045777 9.63 ACE AGT OXT
25 drinking behavior GO:0042756 9.62 OXT REN
26 response to nicotine GO:0035094 9.62 CHRNA1 CHRND CHRNG EDN1
27 glycerol transport GO:0015793 9.61 AQP1 AQP3
28 positive regulation of NAD(P)H oxidase activity GO:0033864 9.61 AGT AGTR1
29 positive regulation of renal sodium excretion GO:0035815 9.61 AGT EDN1 OXT
30 positive regulation of prostaglandin secretion GO:0032308 9.6 EDN1 OXT
31 musculoskeletal movement GO:0050881 9.58 CHRNA1 CHRND
32 regulation of renal sodium excretion GO:0035813 9.57 AGT AGTR1
33 nitric oxide transport GO:0030185 9.56 AQP1 EDN1
34 regulation of blood vessel diameter by renin-angiotensin GO:0002034 9.55 AGT AGTR1
35 regulation of blood volume by renin-angiotensin GO:0002016 9.54 AGT REN
36 skeletal muscle tissue growth GO:0048630 9.52 CHRNA1 CHRND
37 regulation of renal output by angiotensin GO:0002019 9.49 ACE AGT
38 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.33 ACE AGT AGTR1
39 renin-angiotensin regulation of aldosterone production GO:0002018 9.13 AGT AGTR1 REN
40 regulation of vasoconstriction GO:0019229 8.92 ACE AGT AGTR1 EDN1
41 signal transduction GO:0007165 10.26 ADM AGTR1 CHRNA1 CHRND CHRNG GPR182
42 G protein-coupled receptor signaling pathway GO:0007186 10.17 ADM AGT AGTR1 CGA EDN1 GPR182
43 positive regulation of cell proliferation GO:0008284 10.07 ADM AGT CGA EDN1 PKHD1
44 regulation of signaling receptor activity GO:0010469 10.03 ADM AGT CGA EDN1 OXT

Molecular functions related to Oligohydramnios according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular ligand-gated ion channel activity GO:0005230 9.61 CHRNA1 CHRND CHRNG
2 channel activity GO:0015267 9.54 AQP1 AQP3 CHRNG
3 water channel activity GO:0015250 9.46 AQP1 AQP3
4 acetylcholine binding GO:0042166 9.43 CHRNA1 CHRND CHRNG
5 acetylcholine-gated cation-selective channel activity GO:0022848 9.33 CHRNA1 CHRND CHRNG
6 bradykinin receptor binding GO:0031711 9.32 ACE AGTR1
7 acetylcholine receptor activity GO:0015464 9.13 CHRNA1 CHRND CHRNG
8 ligand-gated ion channel activity GO:0015276 9.1 CHRND
9 hormone activity GO:0005179 9.02 ADM AGT CGA EDN1 OXT

Sources for Oligohydramnios

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....